Myocardial Perfusion Imaging Galmydar Rest/Stress

A single center, phase 0/1 clinical imaging study designed to assess the role of [68Ga]Galmydar PET/CT imaging in human subjects.

Inclusion Criteria:Male and female, 18-99 years of age and any race;Have had a prior clinical SPECT MPI positive for ischemia in two myocardial segments and referred for invasive coronary angiography (ICA) or have had a prior clinical SPECT MPI negative for ischemia;Exclusion Criteria:Inability to receive and sign informed consent;Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 6-months prior to SPECT or in the intervening days between SPECT and PET examination;Participants who have received chemotherapeutic agents within 6 months of enrollment;Heart failure (left ventricular ejection fraction ≤ 35%);Known non-ischemic cardiomyopathy;Inability to undergo pharmacologic stress testing with regadenoson (Lexiscan). Contraindications include:Symptomatic bradycardia or second to third degree atrioventricular (AV) block;Pre-existing obstructive lung disease with active wheezing, i.e., COPD, asthma with active wheezing that precludes the safe administration of the pharmacological stress agent according to the approved label;Uncontrolled and severe hypertension (e.g. systolic blood pressure >200 mmHg, diastolic blood pressure >110 mmHg);Baseline hypotension (e.g. systolic blood pressure < 90 mmHg, diastolic blood pressure <50 mmHg);Women who are pregnant or breastfeeding;Severe claustrophobia;Weight ≥ 500 lbs (weight limit of PET/CT table)